TwinBeech Capital’s Travere Therapeutics TVTX Stock Holding History

TwinBeech Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$225K	Sell	3,968 -46,932	-92%	-$2.08M	0.04%	330
2026 Q1	$1.51M	Buy	+50,900	New	+$1.52M	0.16%	190
2025 Q3	–	Sell	-46,730	Closed	-$692K	–	855
2025 Q2	$692K	Sell	46,730 -125,219	-73%	-$2.08M	0.02%	460
2025 Q1	$3.08M	Buy	171,949 +161,780	+1,591%	+$3.28M	0.06%	328
2024 Q4	$177K	Buy	+10,169	New	+$180K	﹤0.01%	567
2024 Q2	–	Sell	-14,718	Closed	-$113K	–	789
2024 Q1	$113K	Sell	14,718 -5,859	-28%	-$49.4K	﹤0.01%	507
2023 Q4	$185K	Sell	20,577 -208,209	-91%	-$1.52M	﹤0.01%	603
2023 Q3	$2.05M	Buy	228,786 +56,940	+33%	+$803K	0.04%	409
2023 Q2	$2.64M	Buy	171,846 +39,218	+30%	+$713K	0.05%	350
2023 Q1	$2.98M	Buy	132,628 +104,855	+378%	+$2.23M	0.06%	321
2022 Q4	$584K	Sell	27,773 -48,831	-64%	-$1.03M	0.01%	578
2022 Q3	$1.89M	Buy	+76,604	New	+$1.98M	0.05%	345

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's TVTX Position: Q2 2026 in Review

TwinBeech Capital reduced its Travere Therapeutics (TVTX) stake by 92% in Q2 2026, selling an estimated $2.08M and leaving 3,968 shares worth $225K. The position accounts for 0.04% of the portfolio, ranked #330.

TwinBeech Capital first reported a position in TVTX in Q3 2022 and has held it in 12 quarters since. The position peaked at $3.08M in Q1 2025. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

TwinBeech Capital held 3,968 shares of Travere Therapeutics worth $225K as of Q2 2026.
TwinBeech Capital sold 46,932 Travere Therapeutics shares in Q2 2026, an estimated $2.08M.
Travere Therapeutics made up 0.04% of TwinBeech Capital's portfolio in Q2 2026, its #330 holding.
TwinBeech Capital first reported a position in Travere Therapeutics in Q3 2022 and has held it in 12 quarters since.
TwinBeech Capital's Travere Therapeutics position peaked at $3.08M in Q1 2025.
319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.